304 related articles for article (PubMed ID: 21826980)
1. [Targeted therapies in breast cancer].
Jerusalem G; Collignon J; Rorive A; Lifrange E; André C; Martin M; Maweja S; Coucke P
Rev Med Liege; 2011; 66(5-6):379-84. PubMed ID: 21826980
[TBL] [Abstract][Full Text] [Related]
2. HER2-positive breast cancer: beyond trastuzumab.
Murphy CG; Fornier M
Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
[TBL] [Abstract][Full Text] [Related]
3. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
4. New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Awada A; Bozovic-Spasojevic I; Chow L
Cancer Treat Rev; 2012 Aug; 38(5):494-504. PubMed ID: 22305205
[TBL] [Abstract][Full Text] [Related]
5. Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer .
Zardavas D; Cameron D; Krop I; Piccart M
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714441
[TBL] [Abstract][Full Text] [Related]
6. Targeting HER2 for the treatment of breast cancer.
Rimawi MF; Schiff R; Osborne CK
Annu Rev Med; 2015; 66():111-28. PubMed ID: 25587647
[TBL] [Abstract][Full Text] [Related]
7. Treatment of HER2-positive breast cancer: current status and future perspectives.
Arteaga CL; Sliwkowski MX; Osborne CK; Perez EA; Puglisi F; Gianni L
Nat Rev Clin Oncol; 2011 Nov; 9(1):16-32. PubMed ID: 22124364
[TBL] [Abstract][Full Text] [Related]
8. [New treatment approaches in breast cancer].
Spirig C; Thürlimann B; Huober J
Ther Umsch; 2008 Apr; 65(4):207-10. PubMed ID: 18622912
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Kümler I; Palshof JA; Andersson M
Breast; 2013 Feb; 22(1):1-12. PubMed ID: 23084121
[TBL] [Abstract][Full Text] [Related]
10. New HER2-positive targeting agents in clinical practice.
Tolaney S
Curr Oncol Rep; 2014; 16(1):359. PubMed ID: 24442625
[TBL] [Abstract][Full Text] [Related]
11. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Martin M; López-Tarruella S
Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
[TBL] [Abstract][Full Text] [Related]
12. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
13. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
14. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling.
Moody SE; Schinzel AC; Singh S; Izzo F; Strickland MR; Luo L; Thomas SR; Boehm JS; Kim SY; Wang ZC; Hahn WC
Oncogene; 2015 Apr; 34(16):2061-71. PubMed ID: 24909179
[TBL] [Abstract][Full Text] [Related]
15. Targeting alternative pathways in HER2-positive breast cancer.
Rastogi P
Oncology (Williston Park); 2010 Apr; 24(5):415-6. PubMed ID: 20480739
[No Abstract] [Full Text] [Related]
16. Treatment of advanced HER2-positive breast cancer: 2018 and beyond.
Pondé N; Brandão M; El-Hachem G; Werbrouck E; Piccart M
Cancer Treat Rev; 2018 Jun; 67():10-20. PubMed ID: 29751334
[TBL] [Abstract][Full Text] [Related]
17. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
[TBL] [Abstract][Full Text] [Related]
18. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
Spector NL; Blackwell KL
J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
20. Targeting the HER2 receptor in metastatic breast cancer.
Orphanos G; Kountourakis P
Hematol Oncol Stem Cell Ther; 2012; 5(3):127-37. PubMed ID: 23095788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
